Leriglitazone appeared to stop disease progress both clinically and via imaging in a small cohort of boys with cerebral ...

Several transcription factors, including farnesoid X receptor (FXR), peroxisome proliferator-activated receptors (PPARs), thyroid hormone receptors (THRs), and liver X receptors (LXRs), have ...

Iqirvo is a first-in-class oral, once-daily peroxisome proliferator-activated receptor (PPAR) agonist. Iqirvo was in-licensed from GENFIT S.A. (NASDAQ:GNFT) in 2021. The expedited approval is ...

A family of agonist drugs for peroxisome proliferator–activated receptor (PPAR-γ) is used in the clinic to battle insulin resistance for the treatment of type 2 diabetes. Their serious side ...